SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (652)12/13/2001 8:56:54 PM
From: LLCF  Respond to of 717
 
Luckily I have none left, but is it worth anything?? This is a completely nutty market, with tax selling one may want to have their $4 bid out there if they think any price is a buy.

DAK



To: Biomaven who wrote (652)12/13/2001 9:16:58 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 717
 
Antrin is still (and may continue to be for some time) shot in dark. Regards the MD (macular degeneration) there is competition from Novartis )on market) and other approach.

As Rick said in '97 (and I was very concern from day one about high doses and BBB):

RE:CEO
"Vuk dlaku mijenja, ali cud ne!"

Miljenko